Gordon is SinoVeda’s Chief Executive Officer, having joined SinoVeda in May 2013 as Vice President, Business Development.

He was previously Executive Director of Corporate Development for the specialty pharmaceutical company Cytochroma Inc. (acquired by OPKO Health, Inc.), where he was responsible for business development and corporate finance. Prior to Cytochroma, Gordon worked in equity research at National Bank Financial and Canaccord Adams, focusing on biotech and healthcare. He started his career with BioChem Pharma and Shire plc in investor relations and business development, at increasing levels of responsibility.

Gordon holds an MBA (Finance) from Queen’s University and an undergraduate degree in Immunology from the University of Toronto, and is a CFA charterholder.

Back to About Us